Teledyne Acquires Maretron
'One of our strategic pillars is to provide customers with the best integration options in the industry, and Maretron strengthens our offering to the market,' said Grégoire Outters, Vice President and General Manager of Teledyne FLIR Maritime and Raymarine. 'By incorporating Maretron's award-winning products into the Raymarine portfolio, we will create a better experience for our customers.'
The addition of Maretron products and engineering expertise expands Raymarine's leading position as a vessel automation solution provider to boat builders and system integrators. The acquisition also includes Maretron's Florida office location, allowing both Raymarine and Maretron to continue to serve the strategic United States Southeast boating market.
The acquisition of Maretron represents Teledyne's eleventh corporate carve-out transaction and second carve-out completed in 2025.
About Teledyne
Teledyne is a leading provider of sophisticated digital imaging products and software, instrumentation, aerospace and defense electronics, and engineered systems. Teledyne's operations are primarily located in the United States, Canada, the United Kingdom, and Western and Northern Europe. For more information, visit Teledyne's website at www.teledyne.com.
About Raymarine
Raymarine designs and produces high-performance marine electronics for mariners who want to eliminate doubt and make the most of their experience and time on the water – whether it's for work or play. With a legacy of marine navigation technology spanning over 80 years, Raymarine products are renowned today for their rugged design, proven performance and unmatched reliability. Our best-in-class sensors and intelligent navigation systems reflect our commitment to giving mariners the freedom to experience the ocean with confidence. Our range of marine electronics is available through a global network of dealers and distributors. For more information, visit www.raymarine.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
Latin American e-commerce co MercadoLibre slips after Q2 profit misses
-- Shares of MercadoLibre (NASDAQ:MELI) slipped 3% in after-hours trading on Monday after the Latin American e-commerce company posted second-quarter earnings that fell well short of Wall Street expectations, even as revenue came in ahead of estimates. The company reported earnings per share of $10.31, missing the consensus estimate of $12.21 by nearly $2. Revenue rose to $6.79 billion, beating expectations of $6.59 billion. MercadoLibre has seen rapid growth across its commerce and payments segments, but rising expenses or shifts in business mix may be weighing on profitability. The stock, which has rallied this year alongside broader gains in e-commerce and digital payments, fell as much as 3% in post-market trading. Related articles Latin American e-commerce co MercadoLibre slips after Q2 profit misses Risks Rising? Smart Money Dodged 46%+ Drawdowns on These High-Flying Names Apollo economist warns: AI bubble now bigger than 1990s tech mania Sign in to access your portfolio
Yahoo
13 minutes ago
- Yahoo
Hims & Hers Health (NYSE:HIMS) Misses Q2 Revenue Estimates, Stock Drops 12%
Telehealth company Hims & Hers Health (NYSE:HIMS) fell short of the market's revenue expectations in Q2 CY2025, but sales rose 72.6% year on year to $544.8 million. On the other hand, the company expects next quarter's revenue to be around $580 million, close to analysts' estimates. Its GAAP profit of $0.17 per share was 13% above analysts' consensus estimates. Is now the time to buy Hims & Hers Health? Find out in our full research report. Hims & Hers Health (HIMS) Q2 CY2025 Highlights: Revenue: $544.8 million vs analyst estimates of $550.8 million (72.6% year-on-year growth, 1.1% miss) EPS (GAAP): $0.17 vs analyst estimates of $0.15 (13% beat) Adjusted EBITDA: $82.24 million vs analyst estimates of $72.2 million (15.1% margin, 13.9% beat) The company reconfirmed its revenue guidance for the full year of $2.35 billion at the midpoint EBITDA guidance for the full year is $315 million at the midpoint, below analyst estimates of $319.4 million Operating Margin: 4.9%, up from 3.5% in the same quarter last year Free Cash Flow was -$69.43 million, down from $47.57 million in the same quarter last year Customers: 2.44 million, up from 2.37 million in the previous quarter Market Capitalization: $14 billion 'It's never been more clear that we are delivering exactly what millions of people have been waiting for: access to personalized, high-quality care that meets people where they are. From the momentum of our business to the results our customers are achieving, we are more confident than ever that our model is helping people optimize their health and realize the benefits of precision medicine,' said Andrew Dudum, co-founder and CEO. Company Overview Originally launched with a focus on stigmatized conditions like hair loss and sexual health, Hims & Hers Health (NYSE:HIMS) operates a consumer-focused telehealth platform that connects patients with healthcare providers for prescriptions and wellness products. Revenue Growth Examining a company's long-term performance can provide clues about its quality. Any business can experience short-term success, but top-performing ones enjoy sustained growth for years. Over the last five years, Hims & Hers Health grew its sales at an incredible 78.1% compounded annual growth rate. Its growth surpassed the average healthcare company and shows its offerings resonate with customers, a great starting point for our analysis. Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. Hims & Hers Health's annualized revenue growth of 68.3% over the last two years is below its five-year trend, but we still think the results suggest healthy demand. We can better understand the company's revenue dynamics by analyzing its number of customers, which reached 2.44 million in the latest quarter. Over the last two years, Hims & Hers Health's customer base averaged 43.3% year-on-year growth. Because this number is lower than its revenue growth, we can see the average customer spent more money each year on the company's products and services. This quarter, Hims & Hers Health achieved a magnificent 72.6% year-on-year revenue growth rate, but its $544.8 million of revenue fell short of Wall Street's lofty estimates. Company management is currently guiding for a 44.4% year-on-year increase in sales next quarter. Looking further ahead, sell-side analysts expect revenue to grow 28.5% over the next 12 months, a deceleration versus the last two years. Still, this projection is healthy and indicates the market sees success for its products and services. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Operating Margin Although Hims & Hers Health was profitable this quarter from an operational perspective, it's generally struggled over a longer time period. Its expensive cost structure has contributed to an average operating margin of negative 1.7% over the last five years. Unprofitable healthcare companies require extra attention because they could get caught swimming naked when the tide goes out. On the plus side, Hims & Hers Health's operating margin rose by 43.9 percentage points over the last five years, as its sales growth gave it operating leverage. Zooming in on its more recent performance, we can see the company's trajectory is intact as its margin has also increased by 13.6 percentage points on a two-year basis. These data points are very encouraging and show momentum is on its side. In Q2, Hims & Hers Health generated an operating margin profit margin of 4.9%, up 1.4 percentage points year on year. This increase was a welcome development and shows it was more efficient. Earnings Per Share Revenue trends explain a company's historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions. Hims & Hers Health's full-year EPS flipped from negative to positive over the last five years. This is a good sign and shows it's at an inflection point. In Q2, Hims & Hers Health reported EPS at $0.17, up from $0.06 in the same quarter last year. This print easily cleared analysts' estimates, and shareholders should be content with the results. Over the next 12 months, Wall Street expects Hims & Hers Health's full-year EPS of $0.80 to grow 4.4%. Key Takeaways from Hims & Hers Health's Q2 Results We enjoyed seeing Hims & Hers Health beat analysts' EPS expectations this quarter. We were also happy its customer base narrowly outperformed Wall Street's estimates. On the other hand, its EBITDA guidance for next quarter missed and its revenue fell slightly short of Wall Street's estimates. Overall, this quarter could have been better. The stock traded down 12% to $55.84 immediately after reporting. Should you buy the stock or not? We think that the latest quarter is just one piece of the longer-term business quality puzzle. Quality, when combined with valuation, can help determine if the stock is a buy. We cover that in our actionable full research report which you can read here, it's free.
Yahoo
13 minutes ago
- Yahoo
AECOM (NYSE:ACM) Misses Q2 Sales Targets
Infrastructure consulting service company AECOM (NYSE:ACM) fell short of the market's revenue expectations in Q2 CY2025, with sales flat year on year at $4.18 billion. Its non-GAAP profit of $1.34 per share was 6.2% above analysts' consensus estimates. Is now the time to buy AECOM? Find out in our full research report. AECOM (ACM) Q2 CY2025 Highlights: Revenue: $4.18 billion vs analyst estimates of $4.32 billion (flat year on year, 3.3% miss) Adjusted EPS: $1.34 vs analyst estimates of $1.26 (6.2% beat) Adjusted EBITDA: $313 million vs analyst estimates of $307.8 million (7.5% margin, 1.7% beat) Management raised its full-year Adjusted EPS guidance to $5.25 at the midpoint, a 1.9% increase EBITDA guidance for the full year is $1.2 billion at the midpoint, in line with analyst expectations Operating Margin: 7%, up from 5.5% in the same quarter last year Free Cash Flow Margin: 6.3%, similar to the same quarter last year Backlog: $24.59 billion at quarter end, up 5.2% year on year Market Capitalization: $14.66 billion 'The strength of our third quarter results, which included outperformance on all key financial metrics, demonstrated the benefits of our competitive edge platform and the high returns we earn on our growth investments,' said Troy Rudd, AECOM's chairman and chief executive officer. Company Overview Founded in 1990 when a group of engineers from five companies decided to merge, AECOM (NYSE:ACM) provides various infrastructure consulting services. Revenue Growth A company's long-term sales performance is one signal of its overall quality. Any business can have short-term success, but a top-tier one grows for years. Unfortunately, AECOM's 4% annualized revenue growth over the last five years was sluggish. This was below our standard for the industrials sector and is a rough starting point for our analysis. We at StockStory place the most emphasis on long-term growth, but within industrials, a half-decade historical view may miss cycles, industry trends, or a company capitalizing on catalysts such as a new contract win or a successful product line. AECOM's annualized revenue growth of 7.3% over the last two years is above its five-year trend, but we were still disappointed by the results. AECOM also reports its backlog, or the value of its outstanding orders that have not yet been executed or delivered. AECOM's backlog reached $24.59 billion in the latest quarter and averaged 2% year-on-year declines over the last two years. Because this number is lower than its revenue growth, we can see the company hasn't secured enough new orders to maintain its growth rate in the future. This quarter, AECOM's $4.18 billion of revenue was flat year on year, falling short of Wall Street's estimates. Looking ahead, sell-side analysts expect revenue to grow 7.3% over the next 12 months, similar to its two-year rate. This projection doesn't excite us and implies its newer products and services will not accelerate its top-line performance yet. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Operating Margin AECOM was profitable over the last five years but held back by its large cost base. Its average operating margin of 4.5% was weak for an industrials business. This result isn't too surprising given its low gross margin as a starting point. On the plus side, AECOM's operating margin rose by 2.5 percentage points over the last five years, as its sales growth gave it operating leverage. This quarter, AECOM generated an operating margin profit margin of 7%, up 1.6 percentage points year on year. The increase was encouraging, and because its operating margin rose more than its gross margin, we can infer it was more efficient with expenses such as marketing, R&D, and administrative overhead. Earnings Per Share Revenue trends explain a company's historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions. AECOM's EPS grew at a spectacular 17.1% compounded annual growth rate over the last five years, higher than its 4% annualized revenue growth. This tells us the company became more profitable on a per-share basis as it expanded. We can take a deeper look into AECOM's earnings to better understand the drivers of its performance. As we mentioned earlier, AECOM's operating margin expanded by 2.5 percentage points over the last five years. On top of that, its share count shrank by 17.8%. These are positive signs for shareholders because improving profitability and share buybacks turbocharge EPS growth relative to revenue growth. Like with revenue, we analyze EPS over a shorter period to see if we are missing a change in the business. For AECOM, its two-year annual EPS growth of 19.7% was higher than its five-year trend. We love it when earnings growth accelerates, especially when it accelerates off an already high base. In Q2, AECOM reported adjusted EPS at $1.34, up from $1.16 in the same quarter last year. This print beat analysts' estimates by 6.2%. Over the next 12 months, Wall Street expects AECOM's full-year EPS of $5.17 to grow 4.1%. Key Takeaways from AECOM's Q2 Results It was good to see AECOM provide full-year EBITDA guidance that slightly beat analysts' expectations. We were also happy its EPS outperformed Wall Street's estimates. On the other hand, its revenue missed. Overall, this quarter was mixed. The stock traded up 1.7% to $114 immediately after reporting. So do we think AECOM is an attractive buy at the current price? If you're making that decision, you should consider the bigger picture of valuation, business qualities, as well as the latest earnings. We cover that in our actionable full research report which you can read here, it's free. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
